News 2017-10-27
2018 CPhI WW — A Window to the Global Pharmaceutical Supply Chain
Continuing a long and respected tradition, CPhI WW’s Annual Meeting was held during October 24-26, 2017 at the Messe Frankfurt Exhibition Center, Germany. As the world’s leading exhibition and meeting place in the area of pharmaceutical ingredients, the event brought global pharmaceutical companies, manufacturers and professionals together in a joint quest for continued supply chain innovation, reliability and quality.
As a top-tier external manufacturing partner and strategic supplier of custom drug intermediates and APIs to many of the world’s leading pharmaceutical companies, a high-powered Porton delegation led by Chairman & CEO Mr. Oliver Ju attended this marquee 3-day event. Porton’s executives had more than 70 meetings with customers at over 50 global pharmaceutical companies including 12 of the Top 20 Big Pharma, such as Janssen, Gilead, Pfizer, Novartis and etc. We also met with dozens of specialty pharmaceutical and biotechnology companies across the US and Europe in reference to ongoing and projected R&D and external manufacturing collaborations.
Also continuing a recently set precedent, Porton hosted a Wine + Tapas Social at our booth for customers, industry stakeholders and media on Wednesday, October 25, 2017. Featuring music, French wines and small plate appetizers, Porton’s executives cultivated valued relationships with many customers and prospective partners during this informal late afternoon event – setting the stage for additional future discussions.
Others
More
News 2026-09-30
Porton Newsletter - September, 2026 Recap
Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001 PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities
News 2026-09-29
Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities
Porton, as the project's CDMO partner, completed process development and manufactured non-GMP toxicology batches and GMP clinical trial materials for LYNC-101's payload-linker.
